International drug companies are threatening to remove medicines from the market if Australia doesn’t offer them a better price. Here’s what’s at stake.
Articles on Drug companies
Displaying 1 - 20 of 22 articles
Before Canada decides to rely on foreign drug regulators to approve new medicines, Health Canada needs to show that it will improve public health.
Canada has no accreditation or inspection system for research ethics boards for clinical drug trials, and no oversight mechanism for the way that they undertake reviews.
We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.
When is it right to reject an expensive new drug?
We suspect these drug company payments are just the tip of the iceberg.
Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
A new study suggests the market alone will not deter or punish pharmaceutical companies whose products turn out to have adverse effects after they have been approved.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
The Covid-19 pandemic has laid bare Europe’s vulnerability to drug-supply disruption. Still, it remains by far the world leader in pharmaceutical products.
An estimated £300m worth of medicine goes unused in the UK every year. But is it safe to take drugs past their expiry date?
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
American companies still face enormous uncertainty about how they’ll be doing business in the UK and EU in the coming years, particularly as the April 12 Brexit deadline draws closer.
Clinical guidelines have a big impact on the care you receive and the drugs you’re prescribed. But one in five doctors who write these guidelines have undisclosed ties to drug companies.
In the run up to the Global Hepatitis Summit 2018, new guidelines for the management of hepatitis C should come under scrutiny – for financial conflict of interest and quality of evidence.
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.
Because we’re still not sure exactly what causes dementia, finding a treatment is difficult.
The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company’s products.
The view of many doctors that “I don’t let myself be influenced” might be the biggest barrier to change.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Dean of the Sol Price School of Public Policy; Distinguished Professor of Pharmacy, Public Policy, and Economics, University of Southern California
-
Postdoctoral Fellow, University of Sydney
-
Epidemiology, University of Cambridge
-
Director, Clem Jones Centre for Ageing Dementia Research, The University of Queensland
-
Professor of Medicine, Stanford University
-
Économiste, rédactrice en chef du Panorama et coordinatrice des Profils du CEPII, CEPII - Institut français d'économie (IFE)
-
Consultant psychiatrist and PhD candidate, Deakin University
-
Professor, Department of Economics and Finance, Business School, University of Canterbury
-
Professor of Medicine and Public Health, University of Colorado Anschutz
-
Maître de conférences, chercheur associé au CEPII, Université Paris Dauphine – PSL
-
Économiste, CEPII - Institut français d'économie (IFE)
-
Clinical Associate Professor of Business Economics, Indiana University